0 167

Cited 91 times in

Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle.

 B. S. Cha  ;  T. P. Ciaraldi  ;  L. Carter  ;  S. E. Nikoulina  ;  S. Mudaliar  ;  R. Mukherjee  ;  J. R. Paterniti Jr.  ;  R. R. Henry 
 DIABETOLOGIA, Vol.44(4) : 444-452, 2001 
Journal Title
Issue Date
CD36 Antigens/metabolism ; Chromans/administration & dosage ; Chromans/pharmacology ; Drug Synergism ; Female ; Glucose/metabolism* ; Glycogen Synthase/metabolism ; Humans ; Lipid Metabolism* ; Male ; Middle Aged ; Muscle, Skeletal/drug effects* ; Muscle, Skeletal/metabolism* ; Nicotinic Acids/administration & dosage ; Nicotinic Acids/pharmacology ; Oxidation-Reduction ; Palmitic Acid/metabolism ; Receptors, Cytoplasmic and Nuclear/agonists* ; Receptors, Cytoplasmic and Nuclear/drug effects ; Receptors, Cytoplasmic and Nuclear/metabolism ; Receptors, Retinoic Acid/agonists* ; Receptors, Retinoic Acid/drug effects ; Receptors, Retinoic Acid/metabolism ; Retinoid X Receptors ; Tetrahydronaphthalenes/administration & dosage ; Tetrahydronaphthalenes/pharmacology ; Thiazoles/administration & dosage ; Thiazoles/pharmacology ; Thiazolidinediones* ; Transcription Factors/agonists* ; Transcription Factors/drug effects ; Transcription Factors/metabolism ; Troglitazone
peroxisome proliferator-activated receptor ; retinoind X receptor ; skeletal muscle ; glucose uptake ; palmitate oxidation ; FAT/CD36
Aims/hypothesis. To determine the independent and potentially synergistic effects of agonists for PPARγ and RXR on glucose and lipid metabolism, as well as gene expression, in human skeletal muscle cell cultures. Methods. Fully differentiated myotubes from non-diabetic subjects and subjects with Type II (non-insulin-dependent) diabetes mellitus were chronically (2 days) treated with LG100 268 (4 μmol/l), an RXR agonist, or troglitazone (4.6 μmol/l), a PPARγ agonist or both, to determine the effects on glucose uptake, activity of glycogen synthase and palmitate oxidation. Results. The combination of both agents increased glucose uptake (60 ± 9 % compared to control subjects) but not either agent alone (16 ± 9 and 26 ± 6 % for LG100 268 and troglitazone, p < 0.01, respectively). The agent LG100 268 alone had little effect on the activity of glycogen synthase but the effect of troglitazone increased with LG100 268 (p < 0.05). With chronic exposure, LG100 268 upregulated palmitate oxidation (53 ± 12 % increase, p < 0.005), in a way similar to troglitazone (68 ± 23 %, p < 0.005). Synergism was observed when both agonists were combined (146 ± 38 %, p < 0.005 vs either agent alone). Treatment with either agent led to about a twofold increase in the expression of fatty acid transporter (FAT/CD36). Troglitazone upregulated PPARγ protein expression, whereas LG100 268 had no effect. Furthermore, neither LG100 268 nor troglitazone had any effect on the protein expression of RXR isoforms or PPARα. Conclusion/interpretation. Co-activation of PPARγ and RXR results in additive or synergistic effects on glucose and lipid metabolism in skeletal muscle, but unlike troglitazone, LG100 268 does not alter expression of its own receptor.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Cha, Bong Soo(차봉수) ORCID logo https://orcid.org/0000-0003-0542-2854
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.